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Abstract
Alzheimer’s disease (AD) and vascular dementia (VaD) are the 
most common subtypes of neurocognitive disorders (NCDs), with 
overlapping clinical presentation and risk factors. Studies on AD brains 
have demonstrated increased extravasation of plasma components 
through a functionally compromised blood-brain barrier (BBB). The 
BBB includes endothelial cells, astrocyte foot processes, basement 
membrane, and pericytes, and its function is to maintain brain 
homeostasis by limiting entry of plasma components into the brain. 
The pathogenesis of VaD is commonly attributed to 
cerebrovascular lesions, and neuroimaging studies have demonstrated 
extravasation of plasma components. Although the pathogenesis of 
AD and VaD is unknown, much evidence suggests that an abnormal 
cerebrovasculature may be a common mechanistic link. The primary 
aims of this review are to highlight studies that embrace or oppose this 
theory, and to examine the potentially causal relationship between 
cerebrovascular abnormalities and pathological hallmarks of AD. 
A major challenge to elucidate the role of the BBB in AD pathology 
has been the inability to demonstrate BBB dysfunction in neuroimaging 
studies. Computed tomography and magnetic resonance imaging 
can detect leakage from larger vessels, significant for VaD, but fail to 
detect smaller chronic vascular leakages common to AD. The latter 
are, however, detected by routine immunohistological techniques 
in postmortem tissues. If we consider AD and VaD from the vascular 
perspective, they have many features in common. By placing these 
diseases along a continuum of vascular pathology manifesting as 
dementia, it becomes apparent that the observed clinical differences 
are mostly attributable to the extent and location of the vascular 
leak. Lastly, we propose a novel hypothesis that we believe can 
potentially account for much of the phenomenology surrounding AD 
and its pathogenesis, including mechanisms of intraneuronal amyloid 
deposition and amyloid plaque formation, and the role of the BBB and 
autoantibodies in this process.  
and Statistical Manual (DSM) - 5th edition stratifies dementia into 
nine subtypes of neurocognitive disorders (NCDs). These include: 
Alzheimer’s disease (AD), frontotemporal lobar degeneration, 
Lewy body disease, vascular disease (previously vascular dementia, 
VaD), traumatic brain injury, substance/medication-induced, HIV 
infection, prion disease, and Parkinson’s disease. AD and VaD (also 
known as vascular cognitive impairment) comprise 60-80% and 
15-20% of the total NCD cases, respectively. As the overwhelming 
majority of the cases, AD afflicts one in nine individuals above the age 
of 65. Presently about 5.3 million Americans are suffering from AD. 
Compared to the most prevalent fatal diseases, only in the case of AD 
is the number of deaths steadily increasing. The seven-fold increase in 
fear of dementia over cancer in the elderly population can perhaps be 
attributed to the lack of effective treatment coupled with inevitability 
of the outcome. This absence of adequate medical intervention is 
largely due to a poor understanding of the pathogenesis and etiology 
of most types of NCDs, AD included. Here we present selected 
studies that have demonstrated an abnormal cerebrovasculature as 
the inciting factor in two of the most prevalent dementias, AD and 
VaD. We also attempt to address some of the controversies that have 
contributed to holding back adequate recognition of the key role 
of the abnormal cerebrovasculature in the pathoetiology of these 
diseases. 
Abnormalities of the Cerebrovasculature may 
Contribute to Impaired Brain Homeostasis, 
Neurodegeneration, and Ultimately Dementia
The phrase “abnormal cerebrovasculature” is terminology 
intended to blanket all kinds of perturbations to blood vessels in the 
cerebral cortex of the brain. Other terminologies implying damage 
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Dementia: The Most Feared Disorder by the Elderly 
Population 
A survey carried out in 500 individuals aged fifty years and older 
in United Kingdom revealed that dementia (by about 70%) is the most 
feared disease [1,2]. The second (trailing by far) most feared disease 
for these participants was cancer (nearly 10%) [1,2]. The Diagnostic 
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to cerebral blood vessels include blood-brain barrier compromise/
breach/permeability, bleeding (micro/mini), cerebral hemorrhage, 
cerebral amyloid angiopathy, arteriosclerosis, and more [3].
Given the importance of maintaining a strictly regulated 
microenvironment in the brain, it is essential to control exactly what 
enters and leaves it. Thus, the fluid that bathes the central nervous 
system, the cerebrospinal fluid (CSF), is not merely an ultrafiltrate 
of blood, but the result of a dynamic interplay between the blood 
and all of its components and the cellular entities that prevent, 
allow, and facilitate transport. In most parts of the cerebral cortex 
and hippocampus, the cerebrovasculature prevents free exchange of 
blood components between the neurons and the general circulation 
[4,5]. This barrier function is now known to be due to the presence 
of tight junctions between neighboring vascular endothelial cells that 
line the walls of cerebral blood vessels.
The monolayer of brain microvascular endothelial cells that forms 
the tight junctions that serve as the physical barrier is emphatically 
referred to as the “blood-brain barrier” (BBB). Other cellular 
structures and associations such as astrocyte foot processes, pericytes, 
basement membrane components, and tight junction proteins further 
strengthen this barrier and are collectively, along with neurons, called 
the “neurovascular unit” [4,6]. Acting as a hindrance to the passage 
of blood-borne pathogens, rampant post-prandial glucose levels, 
soluble immune effector molecules and cells, the primary function 
of the BBB is to preserve an optimal brain homeostasis, an essential 
prerequisite for the normal functioning of neurons operating in a 
complex electrochemical environment [4,5,7,8]. Additional details of 
the BBB are beyond the scope of this article and are covered by many 
experts in the field [4,6,9].    
AD: The Most Prevalent Type of Dementia, 
Characterized by Progressive, Multifactorial 
Neurodegeneration
AD is a neurodegenerative disorder characterized by a progressive 
and irreversible decline in memory and cognition, most commonly 
seen in the elderly. Degenerative changes found in the AD brain 
consist of a loss of neurons and disruption of neuronal circuits in 
cortical and hippocampal brain regions [10-14]. Beta-amyloid (Aβ) 
plaques and neurofibrillary tangles (NFTs) in the brain parenchyma 
are considered to be key microscopic pathological hallmarks of 
AD. More recently, radiological scan studies have demonstrated 
enhanced levels of Aβ peptides in the brains of both AD and control 
subjects [15]. Observations like these corroborate AD as an aging-
associated progressive disease where the pathogenesis could have 
started decades prior to the onset of overt clinical symptoms [16]. 
In addition to extracellular amyloid deposits referred to as amyloid 
plaques, extensive intraneuronal Aβ deposits have been reported in 
both AD and age-matched control cortices and hippocampi, as well 
as in various animal models [17-21]. 
Increasing age is the most important risk factor for AD. Aging 
is associated with significant changes in physical and metabolic 
activities. Receding cortical volume, cerebral atrophy, lacunar 
infarction, and compromised BBB are some of the well-recognized 
changes in aging brains [22-24]. In fact, in a longitudinal study carried 
out on 85 year-old demented and non-demented normal controls, 
Skoog and colleagues reported a leaky BBB in individuals that later 
developed dementia [25]. In addition, metabolic disorders such as 
diabetes mellitus and dyslipidemia, particularly type 2 diabetes and 
hypercholesterolemia, are also associated with aging and have been 
regarded as additional risk factors for AD [26-28]. Furthermore, 
diabetes, hypertension, hyperlipidemia, and cardiovascular diseases 
are widely recognized as comorbid diseases associated with aging 
[29]. Vascular inflammation and increased oxidative stress are also 
reported in the aging population [30]. With millions of identified 
AD cases and additional tens of millions suffering from comorbid 
diseases with AD, the exact impact and cost is very hard to predict. 
For the year 2014, AD was estimated to cost $214 billion in the United 
States. Unfortunately, no cure exists for AD, and the few drugs 
that are available show mild efficacy at symptomatic management. 
This unmet medical need is due in some part to the fact that the 
pathogenesis of AD is not clearly understood, and key features 
remain largely embroiled in controversy amongst experts in the field.
AD: A Disorder of Unknown Etiology but Numerous 
Hypotheses
Even after one hundred years since its discovery, the pathogenesis 
of AD remains elusive and highly contested. Although the presence of 
amyloid (senile) plaques and NFTs is well recognized, how and why 
they appear in the brain is still unclear. These pathological features 
form the basis for the two most prominent hypotheses describing 
AD pathogenesis: the amyloid hypothesis and the tau hypothesis. The 
amyloid hypothesis is based on the deposition or accumulation of Aβ 
peptides generated during the amyloidogenic pathway of amyloid 
precursor protein (APP) processing by β- and γ-secretases. The 
function of APP and Aβ peptides in the brain is still unknown.
NFTs are generated from the hyper-phosphorylated form 
of the Tau protein. Tau belongs to the class of proteins known 
as “microtubule-associated proteins”. Its function is to promote 
microtubule assembly and stabilization, and it is found in all nucleated 
cells [31-34]. In AD pathology, Tau becomes hyper-phosphorylated 
by various kinases, such as glycogen synthase kinase (GSK)-3 [35,36]. 
Hyper-phosphorylated Tau forms neurofibrillary tangles, instead 
of promoting microtubule stability. The structural imbalances 
that ensue cause a spiraling, or corkscrew appearance of axonal 
processes, irreparable neuronal damage, and fibrillar aggregates that 
disrupt cellular transport and architecture [31-33]. These so-named 
“neurofibrillary tangles” are left as remnants within dead neurons. Aβ 
oligomers have been found to associate with microtubules and can 
contribute to the breakdown of the microtubule integrity. It is well 
established that the formation of NFTs occur as a downstream event, 
and amyloid aggregation stimulates a cascade of cellular pathways 
culminating in various kinase activation states [34]. 
Aside from these leading hypotheses, other associations are also 
gaining interest. For example, apolipoprotein E (APOE) is present 
on chylomicrons and intermediate-density lipoproteins [37,38]. It 
plays a role in the catabolism of triglycerides present in lipoprotein 
complexes. However, an isoform of APOE, derived from the ε4 allele, 
has been widely accepted as a genetic risk factor for the late-onset 
variant of AD [37-39]. Alternatively, the cholinergic hypothesis 
attributes aberrant cholinergic firing as a causative factor in AD 
pathogenesis [40]. Numerous abnormalities associated with choline 
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metabolism have also been reported in the cholinergic neurons of 
elderly and AD patients. Moderate alleviation of AD symptoms using 
cholinergic drugs lends credence to this hypothesis. More recently, 
an abnormal cerebrovasculature has also been implicated in AD 
pathology [7,41,42]. Efficient vasoreactivity in brain blood vessels is 
vital to meet the strict oxygen and glucose demands of the brain. Any 
modifications in the brain vasculature could impair normal brain 
homeostasis leading to neurodegenerative changes and impaired 
function [7,41,42].
The Role of a Permeable Blood-Brain Barrier (BBB) in 
AD Pathology is Highly Debated
For this article, we have reviewed the literature that associates an 
abnormal cerebrovasculature with dementia. As mentioned above, 
an abnormal cerebrovasculature has been described using various 
terminologies - BBB compromise/breach/permeability, bleeding 
(micro/mini), cerebral hemorrhage, cerebral amyloid angiopathy, 
and arteriosclerosis. The association between BBB breach and AD 
is not a new concept [43-46]. In fact, the integrity of the BBB has 
been questioned and linked to AD pathology for over three decades 
by several groups. To assess the functionality of the BBB, albumin or 
immunoglobulin (Ig) G levels in CSF and plasma/serum have been 
compared to demonstrate the extent of BBB integrity. Albumin and 
IgG are normally absent in the brain parenchyma, as they cannot 
freely cross the BBB. Thus, their appearance in the CSF indicates a 
permeabilized BBB [43,47].
Radiologic imaging studies using computed tomography or 
magnetic resonance imaging have been employed to analyze BBB 
integrity [43-46]. Immunohistological studies aimed at detecting 
extravasated IgG and albumin within the brain parenchyma have 
also been widely employed to similarly survey the status of the BBB. 
Estimations provided by albumin quotients, IgG indices, and imaging 
studies can be carried out in vivo, while histological studies are 
limited to postmortem tissue. Investigators supporting and refuting 
the role of an impaired BBB in AD pathology can be found in similar 
proportions. Here we briefly review some of the earlier investigations 
corroborating or challenging the BBB’s integrity in AD pathology. 
In vivo studies of BBB compromise
Albumin quotients and IgG indices are used to represent BBB 
leak. Alafuzoff et al. first assayed albumin levels in the CSF and 
serum after Tibbling and colleagues demonstrated its potential 
use in evaluating BBB integrity [48,49]. Alafuzoff and colleagues 
demonstrated significantly higher levels of albumin in CSF of multi-
infarct dementia (a subtype of VaD) and AD (then characterized as 
“senile dementia of Alzheimer type” or “SDAT”) compared to that 
of controls [48]. Another study measured nephelometric readings of 
immunoglobulins and serum protein ratios in the CSF of age-matched 
controls and AD patients – ambulatory and institutionalized [50]. 
Increased CSF/serum ratios for both albumin and IgG were reported 
in both types of AD patients compared to controls. In another effort, 
Blennow and colleagues demonstrated an increased mean albumin 
ratio in AD patients compared to that of healthy controls [51]. An 
interesting study using patients with major depression and AD of 
early and late onset was conducted by Hampel et al. in which they 
reported lower levels of serum albumin and IgG in patients with AD 
and major depression [52]. Among all patient groups, those with late 
onset AD or major depression also demonstrated a significantly lower 
level of serum albumin compared to that of early onset AD patients 
[52]. They also measured pathological CSF/serum ratios of albumin 
and IgG in both AD and major depression patients [52]. Along these 
same lines, Wada and colleagues compared AD patients to controls 
and showed significantly elevated levels of CSF albumin and albumin 
quotients in the AD cohort [53].
Furthermore, in agreement with the “BBB hypothesis”, Skoog and 
colleagues carried out a longitudinal study with 85 year-olds for three 
years [25]. Of the 65 individuals at the beginning of this study, 13 were 
diagnosed with AD, 14 with VaD, and 2 with other dementias. Seven 
individuals developed dementia during the remainder of the study, 
while the other 29 remained non-demented. The authors reported 
an increased mean CSF/serum albumin ratio in AD and dementia 
patients compared to that of controls. Most interestingly, three of 
the non-demented women that later developed dementia had higher 
CSF/serum albumin ratios compared to those who did not develop 
dementia, suggesting BBB breakdown as a process occurring years 
prior to symptom manifestation. In a similar prospective analysis, 
Bowman and colleagues conducted a one-year follow-up study on 36 
mild to moderate AD patients [54]. Using a CSF-albumin index, they 
reported an increased extent of BBB compromise in eight of these 
patients. Additionally, the authors were able to successfully correlate 
the CSF-albumin index with rates of disease progression using a 
Mini-Mental State Examination and annual Clinical Dementia 
Rating sum-of-boxes change and annual ventricular volume change 
[54]. With respect to the CSF/plasma albumin ratio, Algotsson and 
Winblad also reported a greater incidence of BBB breach in male 
AD patients compared to that of female AD patients [55]. They 
suggested gender biases for the measured CSF/serum albumin ratio 
and plasma creatinine levels. More recently, Chalbot and colleagues 
have described a greater sensitivity for CSF secretory Ca2+-dependent 
phospholipase A2 (sPLA2) activity in detecting BBB compromise 
when compared to that derived from the albumin quotient [56]. By 
measuring sPLA2 activity, they detected a greater incidence of BBB 
compromise in AD patients compared to healthy, non-demented 
controls. Taken together, these studies suggest a connection between 
BBB integrity and AD pathology. On the contrary, some investigations 
have failed to observe a compromised BBB in AD patients [57-59].
Histological studies
Using histological sections taken from AD and control brains, 
the integrity of the BBB has been widely tested by detecting the 
presence of blood components in the brain interstitium that 
are normally confined to the vasculature. With an intact BBB, 
immunohistochemistry confirms that the brain parenchyma is 
largely devoid of IgG and albumin. Wisniewski and Kozlowski first 
utilized the local leakage of IgG and albumin to assess BBB integrity 
in brain samples [60]. They reported perivascular leakage of these 
components in SDAT brain sections. The extent of leakage was severe 
in regions demonstrating widespread signs of AD pathology. They 
also reported weak immunoreactivity in control brains and in brain 
regions devoid of amyloid plaques, emphasizing a temporal and 
spatial relationship between local BBB breakdown and the presence 
of AD-related pathology. De Reuck described a greater prevalence 
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of cerebrovascular lesions, micro- or mini-bleeds, in regions of AD 
brains that also demonstrated cerebral amyloid angiopathy [61]. 
Their work also reported mini-bleeds (microscopic, often subclinical, 
and bleeding) in the age-matched controls [61]. 
On the contrary, there are several histological reports that have 
failed to detect any significant difference in the extent of BBB breach. 
Using SDAT and multi-infarct dementia brain samples, Alafuzoff 
and colleagues did not observe any difference in BBB permeability 
between the demented and non-demented age-matched control 
groups [62]. In AD and non-demented controls, Rozemuller’s group 
observed variations in the immunoreactivity of plasma proteins 
[63]. They associated this difference to the fixation period during 
tissue processing rather than an abnormal BBB [63]. Munoz and co-
workers also failed to find evidence of BBB breach in AD and multi-
infarct dementia patients [64]. Along these lines, Tomaimoto et al. 
described an increased BBB breach in white matter lesions in patients 
with cerebrovascular disease compared to those in patients with AD 
[65]. 
Imaging studies
Several groups have used computed tomography (CT), positron 
emission tomography (PET), and magnetic resonance imaging 
(MRI) for detecting BBB breaches in AD and control brains. In spite 
of employing these sophisticated techniques, all of these groups 
have failed to observe any substantial evidence of BBB breach in AD 
and dementia patients [43,47]. Recently, Montagne and colleagues 
demonstrated aging-associated BBB breaches in the hippocampus 
[66]. Using advanced dynamic contrast-enhanced MRI capable of 
quantifying regional BBB permeability in vivo, they demonstrated 
increased BBB compromise in aging individuals [66]. Additionally, 
they reported accelerated BBB compromise in the hippocampus of 
patients with mild cognitive impairment, a well-recognized early 
stage of AD.   
Abnormal Cerebrovasculature and Impaired BBB are 
Detectable in AD Brains using Immunohistochemistry
Our group has examined brain samples from clinically confirmed 
AD and age-matched non-demented controls to investigate the 
state of the cerebrovasculature and integrity of the BBB. Utilizing 
immunohistochemistry, we have mainly studied the extravasation 
of plasma components such as IgG, C1q, and Aβ peptides [18,67]. 
In accord with other studies, we have also taken advantage of 
perivascular leakage of these plasma components and used this 
feature as a tissue biomarker for BBB compromise. In most cases, 
these leak clouds were found surrounding or near the leaky blood 
vessels (termed source blood vessels) or their origins could be easily 
traced. In AD brains, we have observed a greater incidence and extent 
of focal perivascular leakage of IgG, C1q, and Aβ peptides [67]. The 
AD cortex and hippocampus had the greatest extent and number of 
leaky blood vessels [18]. However, these were sometimes coincident 
with adjacent regions that lacked leakage of plasma components and 
thus appeared to be largely normal. As reported by Wisniewski and 
Kozlowski, we have frequently observed some extent of local BBB 
breach in age-matched controls [18,60]. We were further able to 
measure an increased incidence of cerebral amyloid angiopathy in 
the AD cerebrovasculature, in support of work done by Wisniewski, 
Kozlowski, and De Reuck [60,61,68]. Lastly, we also demonstrated 
an increased incidence of perivascular leakage from blood vessels 
that concomitantly exhibited a greater extent of cerebral amyloid 
angiopathy [68].
We have also investigated the integrity of the BBB in several 
animal models: Swiss Webster mice, Sprague Dawley rats, and 
Yorkshire Domestic pigs. In mice, we induced chronic BBB 
compromise by periodically injecting Pertussis Toxin [67]. Upon 
immunohistological examination of these brains, perivascular IgG 
leak clouds were evident and comparable to those seen in the human 
AD cortex. Recently, Sprague Dawley rats at different ages were 
used to study the effects of inhaled anesthetics, such as Sevoflurane 
and Isoflurane, on the BBB and cerebrovasculature [69]. Older rats 
exposed to Sevoflurane showed the greatest extent of BBB breach as 
represented by IgG extravasation. At regions of IgG leakage in these 
rats, the histological picture was again similar to that of AD [18,68,69]. 
Lastly, we showed compromise in BBB structural and functional 
integrity in Yorkshire domestic pigs with long-term diabetes mellitus 
and hypercholesterolemia, both well-known risk factors for dementia 
[70]. The permeability of the BBB in these animals was increased and 
IgG leak clouds were prominent, once again corroborating findings 
in AD and further supporting diabetes as a potent risk factor for AD 
through its effects on the vasculature [70]. Based on these studies, we 
conclude that immunohistochemistry is the most reliable and direct 
method to detect and quantify BBB compromise. Unfortunately, this 
approach comes with the obvious limitation that it is reserved for 
postmortem tissues and, particularly in humans, is thereby subject to 
various degrees of postmortem autolytic changes. In contrast to the 
work of Rozemuller, we have not seen differences in immunoreactivity 
due to fixation technique or chemicals used [59].  
Reservations Limiting the Role of BBB in AD 
Pathology can be Argued
Investigators working in the areas of BBB and AD are split into 
camps that support or refute the purported role of the BBB in AD 
pathology. As mentioned above, our studies have strongly suggested 
that the BBB is universally compromised during AD pathogenesis. 
Here, we offer plausible explanations for some of the reports that 
continue to bring the role of the BBB in AD pathology into question. 
First is the occurrence of BBB breach in apparently healthy control 
individuals [18]. In a recent study using Sprague Dawley rats, we 
observed an aging-associated increase in BBB permeability [69]. 
Likewise, in healthy pigs that served as age-matched controls for 
diabetic and hypercholesterolemic pigs, we demonstrated some 
extent of BBB compromise [70]. In humans, the strongest risk factor 
for sporadic AD is advanced age. Even after the diagnosis of AD, 
however, cognitive abilities continue to decline at a variable pace 
over a period of four to eight years on average. Recent studies now 
suggest that AD-related pathology may be initiated as early as two 
to three decades prior to symptomatic presentation and clinical 
diagnosis [16]. Thus, in a disease as prevalent as AD, it is likely that 
many apparently healthy individuals participating in studies as age-
matched non-demented controls are, in fact, harboring AD-related 
neurodegenerative changes. As such, they are actually asymptomatic 
(or pre-symptomatic) AD patients, and are not true controls at all. 
Starr and colleagues reported a similar extent of BBB leakage between 
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AD and non-demented older controls, giving further support for 
an aging-associated BBB compromise [71]. Based on these data, we 
conclude that the permeability of the BBB increases with aging and 
AD, with variations in the location and extent of leak ultimately 
determining the site and rate of progression of the pathology and the 
timing and type of telltale symptoms that will emerge. 
The second controversy stems from the failure to detect a 
significant indication of BBB breach in AD patients using imaging 
studies. This may be due to the limited resolution and sensitivity 
of this approach [72]. The brain contains many blood vessels of 
varying sizes, and current and widely used imaging techniques are 
not capable of detecting ongoing vascular leakage at the microscopic 
level within the microvasculature as reported by De Reuck [61]. This 
concept is illustrated in Figure 1. To this point, the subclinical and 
apparently asymptomatic micro-bleeds require a degree of sensitivity 
outside the threshold of detection by currently available radiological 
imaging modalities. These bleeds are, however, readily detected in 
immunohistochemical preparations of postmortem tissues. 
The third controversy is the selective appearance of BBB 
compromise in regions of pathology in AD patients. Bowman and 
colleagues reported an increased CSF-albumin index in only eight of 
36 AD patients [54]. In this case, it is possible that the extent of BBB 
compromise in the remaining AD patients had not yet reached a level 
in the brain tissue that is reflected by a detectable threshold of CSF-
albumin index. In diabetic and hypercholesterolemic pigs, we have 
also observed regional variations in Aβ loading by cortical pyramidal 
neurons, apparently paralleling the varied extent of local BBB breach 
in darapladib-treated and control pigs [70]. In fact, in AD brains, 
it is common to observe groups of adjacent pyramidal neurons, 
presumably supported by the same local vascular network, at similar 
stages of intraneuronal amyloid loading. Individual variations, 
particularly those occurring in different regions of the same brain, is 
a major problem for all human studies, as it is very difficult to account 
for all the necessary confounds. Moreover, it becomes an extremely 
arduous task to find older individuals with only one type of chronic 
disease. Besides AD, aging is frequently associated with a wide 
variety of other chronic illnesses - diabetes, cancer, cardiovascular 
diseases, inflammation, traumatic brain injury, etc. It is likely that 
the aforementioned agonal and comorbid states play a crucial role 
in contributing to individual and case-to-case variations that have 
a tendency to lend confusion to our understanding of the disease 
process, a towering problem for the forward progress of research and 
medicine in general. 
BBB Breakdown and Neuron-Binding Immunoglobu-
lin (Ig) G is a Novel “Two-Hit Hypothesis” that could 
Contribute to AD Initiation and Progression
As mentioned previously, the two microscopic pathological 
hallmarks of AD are amyloid plaques and NFTs. Previous studies 
carried out by our group and others have shed light on the generation 
of these Aβ-containing plaques in relation to BBB compromise. This 
work has led us to propose a mechanistic explanation for the generation 
of amyloid plaques, the intraneuronal origin of Aβ peptides, and the 
pathophysiological events leading to BBB compromise. 
The current amyloid hypothesis suggests that Aβ is directly and 
gradually deposited in the extracellular spaces within the brain to 
form amyloid plaques. It does not include the progressive deposition 
and intracellular accumulation of Aβ inside neurons, particularly 
pyramidal neurons, despite the fact that it has been repeatedly 
reported in human, pig, and various mouse transgenic models 
[17-21,67,73,74]. In addition, the prevailing thinking assumes that 
neurons are the main source of the amyloid, and that they secrete 
it into the extracellular space to form plaques. However, for some 
reason, much less attention is given to the possibility that, under 
conditions of BBB breakdown, the peripheral circulation provides 
the major source of the Aβ that is found within neurons and plaques 
during AD pathogenesis [18,68]. In fact, the inverse relationship 
between the number of plaques observed and the number of local 
pyramidal neurons in any given region of the cortex is highly 
suggestive that plaques may actually represent the remnants of dead 
neurons [17-19]. Additional support for a neuronal origin of amyloid 
plaques includes the following: (1) plaques are most abundant in brain 
regions that are normally populated by the cell bodies of neurons, 
especially pyramidal neurons [17-19,73,74], (2) the size of plaques in 
the cerebral cortex of AD brains is directly proportional to the size of 
local neurons from which they are presumably derived [17-19,73,74], 
(3) plaques contain numerous intracellular proteins that are known 
to be somewhat resistant to lysosomal degradation such as cathepsin 
D, ubiquitin, and Tau [17,75,76], and (4) plaques contain neuronal 
mRNAs and DAPI (4′,6-diamidino-2-phenylindole)-positive nuclear 
remnants [17,77]. All of the above hint at remnants of degenerated 
cellular structures within Aβ-containing amyloid plaques [17]. Since 
intact pyramidal neurons in AD brains also show selective and often 
Figure 1: Abnormal cerebrovasculature and BBB breakdown results in 
extravasation of plasma components and is common to both VaD and 
AD. In VaD, cerebrovascular lesions result in an acute leakage of greater 
volumes of plasma components from larger blood vessels. In AD, chronic 
focal leakage of plasma components occurs in smaller blood vessels. The 
smaller blood vessels lack tunics and are dependent on endothelial cells, 
pericytes, astrocytic foot processes, and basement membrane for the 
containment of plasma components. Failure to do so is referred to as BBB 
breakdown. The volume of blood components exuding from larger blood 
vessels in VaD is more readily and easily detected by currently employed 
neuroimaging techniques. However, in the case of smaller blood vessel 
leaks, as is the case with AD, this volume is below the detectable threshold 
for radiological imaging, and can only be visualized in postmortem brain. 
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extensive accumulation of Aβ peptides, we have concluded that the 
degeneration and eventual lysis of a neuron harboring intracellular 
deposits of Aβ peptides can result in the generation of a single dense-
core amyloid plaque [17].
A key feature of the intraneuronal deposition of Aβ42 (the 42 
amino acid-long amyloid species most attributed to AD pathology 
and plaque formation) is its selectivity for pyramidal neurons in AD 
brains. We have proposed that this selectivity is due to the fact that 
most pyramidal neurons in the cerebral cortex highly express the α7 
nicotinic acetylcholine receptor (α7nAChR). Earlier studies carried 
out by Wang and colleagues have demonstrated a high binding 
affinity between α7nAChR and Aβ42 [78,79]. In support of this, 
histological studies have revealed a selective accumulation of Aβ42 
peptides in neurons that express α7nAChR in the AD cerebral cortex 
and hippocampus [19]. Also, using SK-N-MC cells that over-express 
α7nAChR, we have also demonstrated that α7nAChR and Aβ42 are 
co-localized in these cells [19]. In vitro experiments carried out on 
α7nAChR-transfected SK-N-MC cells also shed light on the role that 
α7nAChR plays in endocytosis of exogenous Aβ42. When these cells 
were treated with an inhibitor of endocytosis or an antagonist of 
α7nAChR, they failed to demonstrate Aβ42 accumulation [19]. Moving 
to a mouse in vivo model system, we used fluorescein isothiocyanate 
(FITC)-tagged Aβ40 and Aβ42 peptides to track their internalization 
in the mouse brain [67]. Here, FITC-tagged Aβ40 or Aβ42 peptides 
were introduced into the general circulation by tail vein injection. 
The BBB of these mice was compromised by injecting Pertussis toxin. 
Consequently, these mice demonstrated selective accumulation of 
FITC-tagged Aβ42 peptide in cortical pyramidal and hippocampal 
hilar neurons [67].  
Thus far, all brain regions showing AD-related pathological 
changes have been found to contain neurons that are IgG-positive 
on immunohistochemistry [18,69,70]. Western analysis has been 
used to confirm the presence of brain-reactive autoantibodies in all 
mammals tested thus far, including cow, pig, rat, and mouse, with 
their numbers in any one individual in the thousands [18,70]. The 
ability to translate the simple binary output of a Western blot into 
a complex microarray plate with nearly 10,000 human proteins 
has highlighted the potential utility of autoantibodies for disease 
diagnostics [80-82]. We are now able to stratify selective profiles of 
autoantibodies as biomarkers significant for age, sex, and disease 
state [83]. In addition, we have shown, using adult mouse brain slice 
cultures, that some brain-reactive autoantibodies are able to induce 
Aβ42 internalization in pyramidal neurons [18].    
As mentioned above, in the event of a BBB compromise, various 
plasma components such as Aβ peptides and IgG can enter the 
brain tissue. We have demonstrated the selective binding of IgG to 
pyramidal neurons in the cerebral cortex and hippocampus in regions 
of BBB breach in both AD and age-matched non-demented control 
brains [18]. In studies using adult mouse brain slice cultures, we 
also showed that the extent to which Aβ42 accumulates in pyramidal 
neurons is increased when treated with human serum that includes 
brain-reactive IgG autoantibodies. Interestingly, sera from different 
individuals varied in their potency for driving intraneuronal Aβ42 
accumulation [18]. Taken together, these studies favor the idea that 
intraneuronal accumulation of Aβ42 in pyramidal neurons is triggered 
and driven by local BBB compromise. This BBB compromise 
simultaneously allows access of brain-reactive IgG autoantibodies 
to targets on the surfaces of local neurons, which induces chronic 
endocytosis of bound IgG. At the same time, the chronic influx of 
soluble monomeric and oligomeric Aβ peptides from the peripheral 
circulation into the brain tissue is made possible as a result of the 
BBB breakdown as well. The selective binding of Aβ42 to α7nAChRs 
on the surfaces of the same pyramidal neurons that also bind 
autoreactive IgG thereby drives Aβ42 into these cells via endocytic 
mechanisms [18]. Research carried out by different investigators have 
also demonstrated increased levels of serum autoantibodies in acute 
ischemic stroke, schizophrenia, affective disorders, amyotrophic 
lateral sclerosis, psychosis, personality disorder, Parkinson disease, 
and epilepsy  [84-87]. Many of these studies have also implicated the 
role of compromised BBB in allowing autoantibodies access to the 
brain [84,87-89].
The second hallmark of AD pathology, NFTs, is usually associated 
with advanced stages of AD pathology. In contrast to Aβ plaques, there 
is a scarcity of studies that demonstrate a direct correlation between 
BBB compromise and NFTs. But, there are several studies that have 
reported Aβ-mediated initiation of NFTs. For example, primary 
neurons treated with 20 µM of Aβ42 demonstrated significantly 
increased levels of phosphorylated Tau (Thr 235) [35]. More recently, 
Nery and colleagues have demonstrated the association between 
Aβ fibrils, GSK-3β activity, and phosphorylation of Tau protein in 
zebra fish [36]. The 5dpf larva of zebra fish injected with Aβ42 peptide 
demonstrated weaker avoidance of aversive stimuli compared to 
controls [36]. But, on treatment with lithium chloride, an inhibitor 
of GSK-3β activity, the escape response to stimuli was significantly 
improved. Similarly, intraventricular injection of Aβ42 also increased 
Tau phosphorylation at Ser202 and Thr205 that was inhibited by 
lithium chloride treatment [36]. Lithium has recently gained much 
attention as a potential AD treatment. Many other kinases in the cell 
are also stimulated by Aβ42, which again points to the role of Aβ42 
in promoting production of hyper-phosphorylated Tau protein. 
Although not directly linked to breakdown of the BBB, hyper-
phosphorylated Tau protein is a downstream substrate for many of 
the phosphorylating agents activated by Aβ42, which enters the brain 
parenchyma in the first place through a defective BBB and thus may 
trigger these events.  
Vascular Dementia/Vascular Disease (VaD) Subtype 
of Neurocognitive Disorder Depicts Cerebral Blood 
Vessel Damage
Accounting for roughly one of every five cases of dementia, 
VaD is the second most common cause of dementia or subtype of 
NCD, behind AD [90]. Symptoms include a sudden onset of memory 
dysfunction, immediate history of unsteady gait, loss of executive 
function, and loss of bowel or bladder control, temporally related 
to radiologic findings of blood vessel pathology, stroke in particular 
[90,91]. Upon identification of these symptoms, patients undergo 
neuroimaging tests, and in most cases, these symptoms are associated 
with one or more types of cerebrovascular lesions in the corresponding 
areas of the brain. Most of these investigations reveal extravasation 
of blood components from the larger vasculature as a common 
theme, with concomitant step-wise deterioration of neurological 
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and neurocognitive function. Thus, the designation of VaD arose 
as a category of dementia because it was possible to directly link the 
condition to pathological changes in brain blood vessels that are large 
enough to resolve using imaging. Because large vessels serve larger 
blocks of brain tissue, pathological changes associated with VaD are 
typically acute and accompanied by sudden, overt deterioration or 
loss of function. This VaD phenomenology contrasts the gradual 
progression of symptoms seen in AD patients, as is currently defined.
Neuroimaging, clinical presentations, and detailed patient history 
are used for the diagnosis of VaD, an otherwise difficult condition 
to distinguish from AD. Using CT and MRI, pathology in larger 
vessels may be found which can cause tissue infarction in cortical, 
subcortical, or lacunar distributions. Moreover, hemorrhages in the 
intracerebral, lobar, subarachnoid, and white matter areas are readily 
detected using standard radiologic modalities which can help to 
categorize the VaD [90,91]. However, currently used neuroimaging 
tools have limited sensitivity in detecting mild but chronic types of 
cerebrovascular lesions, leakage, and ischemic manifestations from 
smaller vessel pathology [72]. These so-called micro-bleeds occur 
in smaller vessels that serve proportionately smaller blocks of brain 
tissue so that, by themselves, they are insufficient to cause overt 
clinical symptoms as suddenly as that of typical VaD. In this case, 
the microvascular pathology is generally below the resolution limit 
of typical imaging methods and, as such, the contribution of the 
vasculature to this condition can only be confirmed at autopsy [90]. 
The conspicuous overlap in the microvascular pathology of AD and 
macrovascular pathology of VaD suggests a common mechanistic 
underpinning, again lending credence to the vasculature as an 
upstream landmark by which to categorize both conditions.  
There is a scarcity of research that points to BBB compromise as 
a causal factor in VaD. Mecocci and colleagues did, however, report 
significantly increased CSF albumin and an albumin ratio in multi-
infarct dementia, a type of VaD [58]. Similarly, in a three year follow-
up study with 85 year-old individuals, Skoog and colleagues found 
a significantly increased CSF/serum albumin ratio in VaD patients 
compared to that of age-matched non-demented controls [25]. Some 
of the animal models of VaD have demonstrated incidences of BBB 
compromise [91]. Not surprisingly, the majority of reports aimed at 
understanding the development of VaD implicate lesions in the larger 
blood vessel for its pathoetiology. 
Usually the symptomatology, extent of leakage, and brain 
region will determine the severity and appearance of the disease 
phenotype. Unfortunately, there are several instances in which the 
regions of vascular pathology are not clearly evident. This creates a 
dilemma when giving a diagnosis that determines the treatment. For 
example, the comorbidity of VaD and AD has brought about much 
confusion among investigators in the field. As reported by Barker 
and colleagues, out of 382 dementia patients, 294 demonstrated 
pathological changes similar to AD and VaD as shown by histological 
analysis [92]. Neuropathological studies conducted similar to that 
of Barker’s group have also demonstrated a high degree of overlap 
between AD and VaD [27,41]. These comparable neuropathological 
and vascular changes between VaD and AD could be the result of 
common risk factors, namely aging, hypertension, diabetes mellitus, 
hyperlipidemia, stroke, and cardiac disease [7,92-94]. In conclusion, 
we propose that VaD and AD are similar in that they both display 
vascular pathologies, with the major difference between the two being 
primarily related to the size of the vessels affected and whether the 
symptoms evolve more gradually (as in AD) or in a more acute, step-
wise fashion (as in VaD).
Conclusion
Presently, AD and VaD are the two most common types of 
dementia accounting for up to 95% of all dementias. Unfortunately, 
no single hypothesis currently is able to explain all of the facets 
associated with their pathology. Historically, an abnormal 
cerebrovasculature has been associated with dementia. Here we have 
tried to bring to the forefront and underscore the role of the BBB 
and abnormal cerebrovasculature in the initiation and progression 
of AD and VaD. It would therefore be more accurate to align these 
conditions along a continuum of vascular pathology, rather than 
considering them as two distinct and altogether separate pathological 
entities. Studies carried out by various groups using CT and MRI 
have clearly demonstrated vascular leakage in the patients suffering 
from VaD. In most cases, the clinical symptoms correlate with 
the infarcted or damaged brain regions. On the contrary, these 
neuroimaging techniques have failed to detect comparable levels of 
vascular compromise in AD. For this reason, many have questioned 
the involvement of the abnormal cerebrovasculature in AD pathology. 
Based on histological studies carried out by our group and others in 
AD brains, we propose that the vascular lesions in the AD brain are 
subacute, and the affected blood vessels are too small to be resolved 
using currently employed neuroimaging and other in vivo imaging 
techniques. As the chronically compromised microvasculature 
perturbs brain homeostasis, it may be more accurate to refer to AD as 
“microvascular dementia”.
In our proposed model linking BBB breakdown to AD initiation 
and progression, we are able to successfully explain much of the 
pathology, especially its main hallmark of amyloid plaques. Given that 
amyloid peptides are generated in a multitude of tissue and cell types 
outside of the central nervous system, their abundance in the peripheral 
circulation is well characterized. By means of a permeable BBB, this 
peripheral circulating pool of Aβ (including Aβ42) gains entrance to 
the brain parenchyma and is able to bind neurons, especially those 
pyramidal and hippocampal subsets of cells expressing the α7nAChR. 
Other components of the blood are allowed to percolate through the 
same brain regions where Aβ42 leaks, including neuron-binding IgG 
autoantibodies. These IgG species have been demonstrated to bind 
to the same neurons that bind Aβ42, and both are co-localized in the 
lysosomal compartments within these neurons, further pointing to 
these two entities being mechanistically linked. Intraneuronal Aβ42 
has been shown to activate a number of kinases that phosphorylate 
Tau as its substrate, promoting microtubule instability that results 
in axonal collapse, recoiling back towards the cell body. Alongside 
this cellular demise and upon chronic taxing of these cells with 
the metabolic instability from chronic Aβ42 and IgG binding and 
internalization, neurons undergo necrosis and form what can be 
visualized on autopsy as amyloid plaques and NFTs. Both events 
occur downstream of a broken BBB. 
We believe that AD- and VaD-associated vascular changes are 
incurred as a result of more than one type of insult. Aging, diabetes, 
hypertension, dyslipidemia-associated comorbid conditions, 
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and trauma may increase one’s vulnerability for an abnormal 
cerebrovasculature. The incidentally impaired BBB is only one of the 
many contributing factors. But it occurs as an important fulcrum by 
which the rest of the mechanism pivots and proceeds. Our research has 
invariably pointed to chronic cerebrovascular leakage as the common 
upstream event in the pathogenesis of AD and VaD. Unfortunately, 
the currently employed in vivo techniques are unable to detect these 
microvascular lesions, thus calling for technical improvements that 
will make their detection possible. In our opinion, the inability to 
detect, locate, and quantify BBB compromise in vivo is the greatest 
challenge. Being able to detect BBB compromise and a leaky 
vasculature at subacute levels would be helpful for early diagnosis, 
prognosis, and treatment success. Therapeutic efforts aimed at 
strengthening the BBB at early stages of AD and VaD pathogenesis 
could be the most promising treatment strategy for preventing AD 
and other types of NCDs.  
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